Source: ERJ Open ResERJ Open Research, Vol 10, Iss 4 (2024)ERJ Open ResearchERJ Open Research, 2024, 10 (2), pp.00976-2023. ⟨10.1183/23120541.00976-2023⟩

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Faecalibacterium duncaniae as a novel next generation probiotic against influenza

Authors : Loïc Chollet; Séverine Heumel; Lucie Deruyter ...

Subjects: SCFAs; 0301 basic medicine; [SDV]Life Sciences [q-bio]

Source: Front ImmunolFrontiers in Immunology, Vol 15 (2024)Frontiers in ImmunologyFrontiers in Immunology, 2024, 15, ⟨10.3389/fimmu.2024.1347676⟩Frontiers in Immunology, 2024, 15,

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Authors : Pons-Tostivint, Elvire; Ezzedine, Remy; Goronflot, Thomas ...

Subjects: [SDV.CAN]Life Sciences [q-bio]/Cancer; [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy; [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract

Source: ISSN: 0169-5002 ; Lung Cancer ; https://hal.science/hal-05071340 ; Lung Cancer, 2024, 194, pp.107887. ⟨10.1016/j.lungcan.2024.107887⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Eugenol Inhibits Neutrophils Myeloperoxidase In Vitro and Attenuates LPS-Induced Lung Inflammation in Mice

Authors : Chniguir, Amina; Saguem, Mohamed Hedi; Dang, Pham My-Chan ...

Subjects: eugenol; neutrophils; oxidative stress

Source: ISSN: 1424-8247 ; Pharmaceuticals ; https://hal.science/hal-04777892 ; Pharmaceuticals, 2024, 17 (4), pp.504. ⟨10.3390/ph17040504⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab

Authors : Bourdin, Arnaud; Chupp, Geoffrey; Jackson, David ...

Subjects: Adverse events; Asthma; Biologic agents

Source: ISSN: 2213-2198 ; EISSN: 2213-2201.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Targeted therapy in eosinophilic chronic obstructive pulmonary disease

Authors : Fieldes, Mathieu; Bourguignon, Chloé; Assou, Said ...

Subjects: 03 medical and health sciences; 0302 clinical medicine; [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract

Source: ERJ Open ResERJ Open Research, Vol 7, Iss 2 (2021)ERJ Open ResearchERJ Open Research, European Respiratory Society, 2021, 7 (2), pp.00437-2020.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial: a multicentre, randomised, open-label, phase 3 trial

Authors : Baas, Paul; Scherpereel, Arnaud; Nowak, Anna ...

Subjects: Male; [SDV.IMM] Life Sciences [q-bio]/Immunology; EMC OR-01

Source: The Lancet Digital HealthThe Lancet Digital Health, 2021, 397 (10272), pp.375-386. ⟨10.1016/S0140-6736(20)32714-8⟩The

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Curcumin-mediated NRF2 induction limits inflammatory damage in, preclinical models of cystic fibrosis

A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview

Healthcare Resource Utilisation and Costs of Mepolizumab Initiation: A 5‐Year National Cohort Analysis

Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life

Faecalibacterium duncaniae as a novel next generation probiotic against influenza

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Eugenol Inhibits Neutrophils Myeloperoxidase In Vitro and Attenuates LPS-Induced Lung Inflammation in Mice

MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab

Targeted therapy in eosinophilic chronic obstructive pulmonary disease

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial: a multicentre, randomised, open-label, phase 3 trial

اتصل بنا

اتبع